X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

GAC Beneficiary Houston Methodist Investigates Immunotherapy Techniques to Curb COVID-19

Content Team by Content Team
7th April 2020
in News
GAC Beneficiary Houston Methodist Investigates Immunotherapy Techniques to Curb COVID-19

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Golfers Against Cancer takes pride in identifying research projects dedicated to specific work targeting various forms of cancer. One such area the organization has supported involves immunotherapy. According to the Cancer Research Institute, it is defined as a form of treatment that uses the power of the body’s own immune system to prevent, control and eliminate cancer.

One of GAC’s beneficiaries – Houston Methodist Hospital — is involved in a number of cancer research efforts utilizing immunotherapy. GAC is proud to help fund some of these projects. Now Houston Methodist is looking at a form of immunotherapy in hopes of curbing the effects of COVID-19. They were the first hospital in the nation to try the experimental therapy which involves a transfusion of blood from a patient who has recovered from COVID-19 into a critically ill patient.

The treatment has been fast-tracked as the death toll from the pandemic continues to rise. The Food and Drug Administration approved Methodist’s “emergency investigational new drug” application to test the therapy.

Plasma from someone who has recovered from COVID-19 contains antibodies made by the immune system to attack the virus. The hope is that transfusing such plasma into a patient still fighting the virus may transfer the power of the antibodies into a healing, possibly life-saving therapy.

GAC Founder and Co-Chair Bobby Jones said there are a number of organizations helping in this cause. In addition to Houston Methodist, MD Anderson is another GAC beneficiary that is a leader in seeking solutions to critical diseases. Their own Dr. Jim Allison, who was GAC’s Person of the Year in 2018, won the Nobel Prize for his work in immunology. And we’re also proud that our GAC Dinners for Cancer Research in New York City and Boston have supported similar work at institutions in those areas.

Though it is too early to know if the therapy is benefiting patients, medical scientists remain hopeful.

Dan McIntyre, who is the GAC Co-Chair along with Jones, says “I think I speak for all of the board members, sponsors and volunteers of our organization when I say that we couldn’t be more pleased that the dollars we raise provide so much value to medical research. And sometimes therapies targeting cancer may, in one form or another, help in curing other diseases like the one our nation is faced with today.”

Previous Post

Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19

Next Post

Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In